User login
In his March podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses two original research articles that focus on women who have survived cancer, one that looks at the effects of ArginMax on sexual functioning and quality of life in female cancer survivors, and another that examines the need for decision and communication aids among breast cancer survivors. Also included in this month’s line-up of original research is a report on the cost of palliative external beam radiotherapy for bone metastases in patients with prostate cancer and a study of the impact of an electronic medical record intervention on the use of growth factor in patients with cancer. The regular Community Translations column features the recently approved combination therapy, palbociclib plus letrozole, for first-line treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Dr Henry rounds off the podcast with a discussion the Journal Club’s entry, which this month focuses on new approvals, genetic testing, and maintenance therapy in women with ovarian cancer.
In his March podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses two original research articles that focus on women who have survived cancer, one that looks at the effects of ArginMax on sexual functioning and quality of life in female cancer survivors, and another that examines the need for decision and communication aids among breast cancer survivors. Also included in this month’s line-up of original research is a report on the cost of palliative external beam radiotherapy for bone metastases in patients with prostate cancer and a study of the impact of an electronic medical record intervention on the use of growth factor in patients with cancer. The regular Community Translations column features the recently approved combination therapy, palbociclib plus letrozole, for first-line treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Dr Henry rounds off the podcast with a discussion the Journal Club’s entry, which this month focuses on new approvals, genetic testing, and maintenance therapy in women with ovarian cancer.
In his March podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses two original research articles that focus on women who have survived cancer, one that looks at the effects of ArginMax on sexual functioning and quality of life in female cancer survivors, and another that examines the need for decision and communication aids among breast cancer survivors. Also included in this month’s line-up of original research is a report on the cost of palliative external beam radiotherapy for bone metastases in patients with prostate cancer and a study of the impact of an electronic medical record intervention on the use of growth factor in patients with cancer. The regular Community Translations column features the recently approved combination therapy, palbociclib plus letrozole, for first-line treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Dr Henry rounds off the podcast with a discussion the Journal Club’s entry, which this month focuses on new approvals, genetic testing, and maintenance therapy in women with ovarian cancer.